Prelude Therapeutics (PRLD) Cash from Operations Growth (1y) (2020 - 2026)
Powered by 
Analysis
Prelude Therapeutics (PRLD) Cash from Operations Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 42.76% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.58% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 151.70% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 100.14% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 56.79% |
| 10 | Prelude Therapeutics | 539.17 Mn | 258.54 Mn | - | 40.27% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 40.27% |
| Mar 31, 2026 | 36.65% |
| Dec 31, 2025 | 211.45% |
| Sep 30, 2025 | 29.97% |
| Jun 30, 2025 | -13.09% |
| Mar 31, 2025 | -7.68% |
| Dec 31, 2024 | 12.02% |
| Sep 30, 2024 | -6.28% |
| Jun 30, 2024 | 16.67% |
| Mar 31, 2024 | -5.50% |
| Dec 31, 2023 | -2.84% |
| Sep 30, 2023 | -25.66% |
| Jun 30, 2023 | -49.82% |
| Mar 31, 2023 | -37.63% |
| Dec 31, 2022 | 10.80% |
| Sep 30, 2022 | 6.13% |
| Jun 30, 2022 | 7.25% |
| Mar 31, 2022 | -35.63% |
| Dec 31, 2021 | -73.11% |
| Sep 30, 2021 | -74.09% |